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Introduction
Cisplatin is an anti-cancer chemotherapeutic drug that is administered to treat a large number of cancers such as those of the ovary, head and neck, cervix and bladder, carcinomas as well as small-cell and non-small-cell lung cancers. [1] [2] [3] [4] [5] However, resistance to cisplatin is a clinical problem for the treatment of some tumors. 6 After an initial response to chemotherapy, tumors subsequently show the minimal responsiveness to cisplatin. 1, 2, 7 Besides direct cytotoxic effects, cisplatin has also the potential to enhance radiation-induced cell killing. [8] [9] [10] Cisplatin as a radiosensitizer increases the damage to the nuclear DNA of malignant cells, enhancing the anti-neoplastic efficacy of the radiotherapy. 9, 10 The combination of cisplatin and radiation is a common treatment modality with synergistic effects for cancers. 4, 5, 8, 9, 11 Several in vitro and in vivo studies have shown higher response rates, prolonged mean survival, increased survival rates, longer local recurrence-free survival rates, and considerable organ preservation with the use of cisplatin in combination with external radiotherapy. [8] [9] [10] [11] Indeed, it has been proven that cisplatin enhances the cytotoxicity of radiation on cells in vitro, on experimental tumors in vivo and in solid tumors in the clinic. [12] [13] [14] Many studies have been performed to potentiate cisplatin antitumor effectiveness. One way to increase the radiosensitizing effect of cisplatin can result from the increase of the cisplatin intracellular accumulation. Several studies have been conducted using different drug delivery systems to increase the amount of cisplatin in the tumor cells. 8, [14] [15] [16] [17] [18] Electropermeabilization is a physical method that uses short and intense electric pulses to facilitate drug delivery into the cells. 19, 20 Electrochemotherapy (ECT) combines the administration of specific chemotherapeutic drugs (bleomycin or cisplatin) with the application of electric pulses to the tumors to locally increase drug uptake and thus drug effectiveness. 17, 21 Electrochemotherapy with bleomycin and cisplatin was elaborated in vitro, in vivo and in clinical trials. 15, 16, [21] [22] [23] [24] [25] Besides permeability, electroporation has other effects like a transient and reversible reduction of the blood flow. 26 This reduction may contribute to the entrapment of the drug in the tumor, thereby providing more time for the drug to act. As this effect would reduce drug wash-out from the tumor, it could play a role in antitumor efficiency.
It has been demonstrated that the electroporation of tumors increases the radiosensitizing effect of cisplatin on small experimental tumors. 27, 28 The enhanced radiosensitizing effect of cisplatin is actually due to the increased electroporationmediated cisplatin delivery into the tumor cells. 29 These initial studies used an already efficient dose of radiotherapy (RT) which was delivered to SA-1 fibrosarcoma transplanted in mice, combined to electrochemotherapy using cisplatin as well as small tumors in mice. 27 The aim of the present study was to evaluate the efficiency of electrochemotherapy with cisplatin combined with a single radiotherapy dose on an animal model tumor of breast adenocarcinoma to determine the potentialities of this combination. Two sub-optimal radiotherapy conditions, 3 Gy or 5 Gy, unable to generate long term partial responses in this tumor model, were applied in these combinations. Moreover, it was decided to treat very large experimental tumors, of an average volume of 630 mm 3 , to assess the efficacy of the treatment alone or in combination in a preclinical model exploring the possibility of efficiently treating large lesions.
Materials and methods

Mice and tumors
Female Balb/C mice, purchased from the Pasteur Institute (Tehran, Iran) were maintained at 25˚C with natural day/night cycle for 10 days for adaptation. Mice were 6-8 weeks old at the beginning of the experiments. A fragment (4 mm 3 ) of a spontaneous mouse mammary tumor (an invasive ductal carcinoma) was transplanted subcutaneously into the flank of each animal. 30, 31 Two weeks after the implantation, when the tumors reached approximately 630 mm 3 in volume (12-15 mm in diameter), the mice were randomly divided into the experimental groups (8-10 animals for each control and each experimental group). The study was approved by the local Research and Medical Ethics Committee, in accordance with the Shahid Beheshti University of Medical Sciences Guidelines for the Care and Use of Laboratory Animals.
Cisplatin
Cisplatin (50 mg/ml, Ebewe Pharma, Austria) was diluted with 0.9% NaCl the day of the treatment. Cisplatin at a dose of 8 mg/kg was injected intratumorally and the injected volume was adjusted to deliver 0.02 ml of this cisplatin solution per gram of body weight.
Electrochemotherapy
Two flat stainless steel plates were mounted on a caliper to serve as 20 x 20 mm parallel electrodes. A distance between electrodes was adjusted by rolling of the caliper depending on the tumor size. The voltage value was then set in an ECT-SBDC device (with a maximal output voltage of 1400 V) to gen-erate electric pulses with a voltage to distance ratio of 1000 V/cm. The electrodes and the ECT-SBDC device were designed in the electromagnetic laboratory of the Medical Physics department of Tarbiat Modares University, Tehran, Iran. Eight squarewave electric pulses (two trains of 4 pulses) of 1000 V/cm amplitude, with a pulse duration of 100µs and repetition frequency 1 Hz, were delivered by the two parallel electrodes which were placed on the skin at the opposite sides of the tumor. An optimal contact between the electrodes and the skin was assured by means of a conductive gel. In all the electrochemotherapy groups, mice were treated with the electric pulses 1 min after the cisplatin injection.
Radiotherapy
A cobalt-60 unit (Theraton 780, Canada) was used to locally deliver a single dose of 3 Gy or 5 Gy at a dose rate of 0.6 Gy/min (3 Gy in 5 min) or 0.71 Gy/min (5 Gy in 7 min). Irradiation was performed frontally. As the smallest field covered by the Cobalt beam was 4 x 4 cm 2 , the mouse's body around the tumor was shielded using lead blocks so as to leave only the tumor exposed to the irradiation beam.
Study protocol
The experimental groups included: untreated tumors as controls, tumors treated with cisplatin, electric pulses or radiotherapy alone, tumors treated by electrochemotherapy (that is cisplatin injection followed by the local application of electroporative electric pulses) and tumors treated with the combination of cisplatin or electric pulses and radiotherapy. In the combination of cisplatin or electroporation with local radiotherapy, tumor-bearing mice were irradiated 30 min after the cisplatin injection or the electric pulses delivery, to provide the time to cisplatin to enter the cells.
Treatment evaluation
Tumor growth was monitored, every three days, by measuring two mutually orthogonal tumor diameters (e1 being the larger tumor diameter and e2 the largest diameter orthogonal to e1). Tumors were rather spherical and tumor volumes were calculated by the formula V= π/6 × e1× e2 2 . From the tumor growth curves, tumor-doubling time (DT) was determined for each individual tumor. Tumor growth delay (GD) was calculated by subtracting the mean tumor volume doubling time of the untreated tumors (control) from the mean tumor volume doubling time of each experimental group. Inhibition ratio, expressed in percent, was calculated at day 30 after the treatment by the formula [1-(treated tumor average volume/untreated tumor average volume)] x100%. Partial response (PR) was a decrease by more than 50% of the tumor volume. Complete response (CR) was the absence of tumor for more than 100 days. CDDP = cisplatin; EP = electric pulses; ECT = electrochemotherapy; IR = irradiation; n = number of mice in the experimental group; DT = tumor doubling time; GD = growth delay; PR = partial response; CR = complete response Normalized volumes at day N for each animal were calculated by dividing the tumor volume Vn at day N after the treatment by the average tumor volume V0 at day 0 that is at the day of the treatment (Vn/V0).
Statistical analysis
All data were tested for normality of distribution. The ANOVA test with repeated measures was used to evaluate statistical significance of differences between experimental and control groups at different times. A p-value<0.05 was considered significant in the statistical tests (*p <0.05).
Results
As shown in Table 1 and Figure 1 , cisplatin (at a dose of 8 mg/kg) as a single treatment delayed the tumor growth up to 5.5 days with an inhibition ratio of 33%. Tumors that were treated with electric pulses alone (8 pulses, 1000 V/cm, 100µs duration, at 1 Hz repetition frequency) displayed a tumor growth delay of only 2 days with an inhibition ratio of 32% (Table 1 ) and with no partial or complete responders with neither of both treatment modalities.
In the electrochemotherapy group, in which tumors were exposed to electric pulses 1 min after the cisplatin injection, a prolonged tumor growth delay (up to 15.5 days) was observed (p <0.05). The inhibition ratio reached 61% (Table 1) . Thus, electrochemotherapy was more effective than either cisplatin alone or the application of electric pulses alone, with moreover 30% partial response for the first 9 days (p <0.05).
With local irradiation alone (Table 1 and Figures  1 and 2) , the higher dose (5 Gy) resulted in a growth delay up to 20.6 days. Tumors irradiated with a single dose of 3 Gy resulted in a tumor growth delay of 11.1 days and an inhibition ratio of 63% (Table 1) . Some partial responses (25%) were observed within the 15 days that followed the administration of 5 Gy, but only 11% with 3 Gy.
When the administration of cisplatin was combined with local irradiation performed 30 min after the drug injection, the treatment of tumors resulted in tumor growth delays and inhibition ratios of 11.3 days and 61% respectively with a 3 Gy radiation and of 21.0 days and 75% with a 5 Gy irradiation (Table 1 ). These results demonstrate that a dose of 5 Gy was more effective. This is also borne out by the fact that 25% partial responses were observed for up to 15 days with the 3 Gy irradiation, whereas only 11% partial responses were recorded up to 12 days following the combination of cisplatin and 3 Gy irradiation (p <0.05).
When electric pulses were combined with local irradiation delivered 30 min after the electric pulses application, an improved antitumor effect was not observed compared to irradiation alone. Tumor growth delays of 8.8 days and inhibition ratio of 51% after 3 Gy and of 17.8 days and 59% after 5 Gy were scored (Table 1) . With 5 Gy, one partial response (12.5%) was achieved for 15 days with no partial responders after 3 Gy.
Irradiation of tumors pretreated with electrochemotherapy prolonged the tumor growth delay up to 25.7 days and 38.6 days at 3 Gy and 5 Gy respectively. The inhibition ratio reached 76% for the 3 Gy irradiation and 87% for 5 Gy. Ten per cent of partial responses after 30 days were observed with electrochemotherapy followed by 3 Gy, though without complete responders. In contrast, the electrochemotherapy with a 5 Gy irradiation resulted in a higher percentage of partial regressions (37% of the tumors were still in partial response 30 days after the treatment). Moreover, 25% of the mice were still in complete remission 100 days after the treatment (Table 1 and Figure 3) . Again, the combination with 5 Gy was significantly (p <0.05) more efficient than the combination with 3 Gy. Even in this group, no body weight loss or skin desquamation was reported. Only a hair loss was observed in all the groups that were irradiated, locally at the level of the irradiation site.
In summary, in all the cases, the combination with γ-radiation resulted in a larger antitumor efficacy than without the combination with γ-rays.
Discussion
In this study, the therapeutic effects of cisplatin, electroporation, γ-radiation and combination of these treatments were evaluated in a murine invasive ductal carcinoma tumor model. Our data confirm and extend previous findings [16] [17] [18] showing that the delivery to tumors of electric pulses and cisplatin enhances the cisplatin-induced radiosensitization.
Electroporation combined with cisplatin has shown a significant effectiveness both in vitro and in vivo, as well as in clinical studies in the treatment of patients with cutaneous tumor nodules. [15] [16] [17] [18] 24, 25 Although the increased radiosensitizing effect of cisplatin using electroporation has been shown in EAT carcinoma and LPB sarcoma cells 27, 28 , data on radiosensitization for large tumors, of a size closer to clinical situations, have not yet been reported. In this study, this issue was addressed and using local γ-radiation with single doses of 3 Gy or 5 Gy of Cobalt-60 γ-rays in combination with electrochemotherapy with cisplatin on large invasive ductal carcinoma tumors as a model for the treatment of large breast tumors.
Our study confirms that electrochemotherapy was more effective than individual treatments using cisplatin or electric pulses alone which is consistent with previous reports. [16] [17] [18] 27, 28 When electrochemotherapy with cisplatin was combined with local irradiation, the antitumor efficiency was doubled. This three-modality therapy was better than electrochemotherapy, cisplatin combined with local tumor irradiation and electric pulses combined with irradiation. In addition, some tumors were still in complete remission 100 days after the treatment at single dose of 5 Gy. It is important to highlight that the irradiation doses used in the present study (a single 3 Gy or 5 Gy dose) are lower than the doses used in the previous experimental studies with cisplatin reported here above. 27, 28 Indeed, Sersa et al. used a dose of 15 Gy for electrochemotherapy with cisplatin combined with irradiation on the EAT tumor animal model. 27 However, there are studies that demonstrated an increase of the tumor curability dose (TCD50) for both cisplatin (being 1.6) and bleomycin (1.9). 32, 33 This study concentrated on electrochemotherapy with cisplatin, as cisplatin is a radiosentizer, with the aim also to show that electrochemotherapy can radiosensitize the tumors. However, the initial goal was to determine whether electrochemotherapy efficacy could be increased by irradiation even in large tumors. Indeed, using about the same dose rate 2.2 Gy/min (10-20 Gy), Sersa et al. showed that efficacy of electrochemotherapy with bleomycin (a molecule considered a radiomimetic but not a radiosensitizer) was increased with irradiation, on SA-1 and CaNT tumor models. 32 Finally it is important to report that our results are also in agreement with two clinical studies 34, 35 reporting that electrochemotherapy in combination with irradiation is an effective and safe treatment for tumors of various origins in patients, thus on lesions of a size at least comparable to those treated in this study.
In conclusion the results of this study demonstrate that electrochemotherapy with cisplatin radiosensitized the tumors to a single low irradiation dose (3 Gy or 5 Gy of Cobalt-60 γ-rays) on invasive ductal carcinoma tumors. Moreover, this three-modality combined treatment was useful for the treatment of large lesions even at sub-optimal doses of irradiation. Complete response of very large tumors could be achieved after a single session with the combined multimodality treatment.
